Welcome to the InfoSci Platform
Nanotechnology for Omics-Based Ocular Drug Delivery

Nanotechnology for Omics-Based Ocular Drug Delivery

Anjali Hirani, Aditya Grover, Yong Woo Lee, Yashwant Pathak, Vijaykumar Sutariya
Copyright: © 2017 |Pages: 16
ISBN13: 9781522505495|ISBN10: 1522505490|EISBN13: 9781522506386
DOI: 10.4018/978-1-5225-0549-5.ch013
Cite Chapter Cite Chapter

MLA

Hirani, Anjali, et al. "Nanotechnology for Omics-Based Ocular Drug Delivery." Oncology: Breakthroughs in Research and Practice, edited by Information Resources Management Association, IGI Global, 2017, pp. 366-381. https://doi.org/10.4018/978-1-5225-0549-5.ch013

APA

Hirani, A., Grover, A., Lee, Y. W., Pathak, Y., & Sutariya, V. (2017). Nanotechnology for Omics-Based Ocular Drug Delivery. In I. Management Association (Ed.), Oncology: Breakthroughs in Research and Practice (pp. 366-381). IGI Global. https://doi.org/10.4018/978-1-5225-0549-5.ch013

Chicago

Hirani, Anjali, et al. "Nanotechnology for Omics-Based Ocular Drug Delivery." In Oncology: Breakthroughs in Research and Practice, edited by Information Resources Management Association, 366-381. Hershey, PA: IGI Global, 2017. https://doi.org/10.4018/978-1-5225-0549-5.ch013

Export Reference

Mendeley
Favorite

Abstract

Millions of people suffer from ocular diseases that impair vision and can lead to blindness. Advances in genomics and proteomics have revealed a number of different molecular markers specific for different ocular diseases, thereby optimizing the processes of drug development and discovery. Nanotechnology can increase the throughput of data obtained in omics-based studies and allows for more sensitive diagnostic techniques as more efficient drug delivery systems. Biocompatible and biodegradable nanomaterials developed through omics-based research are able to target reported molecular markers for different ocular diseases and offer novel alternatives to conventional drug therapy. In this chapter, the authors review the pathophysiology, current genomic and proteomic information, and current nanomaterial-based therapies of four ocular diseases: glaucoma, uveal melanoma, age-related macular degeneration, and diabetic retinopathy. Omics-based research can be used to elucidate specific genes and proteins and develop novel nanomedicine formulations to prevent, halt, or cure ocular diseases at the transcriptional or translational level.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.